By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    falsified drugs
    What Are the Health Risks of Falsified Drugs?
    July 15, 2024
    chronic disease
    The Role of Compliance Packaging in Chronic Disease Management
    November 4, 2024
    How to Deal with Ethical Dilemmas in Social Work
    How to Deal with Ethical Dilemmas in Healthcare Social Work
    March 6, 2025
    Latest News
    Beyond Nutrition: Everyday Foods That Support Whole-Body Health
    June 15, 2025
    The Wide-Ranging Benefits of Magnesium Supplements
    June 11, 2025
    The Best Home Remedies for Migraines
    June 5, 2025
    The Hidden Impact Of Stress On Your Body’s Alignment And Balance
    May 22, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    (Some) Docs Launch War on Overutilization
    February 19, 2012
    Ribs on BBQ
    Meat and Mortality: Does Eating Meat Decrease Your Lifespan?
    March 10, 2013
    Match Day Looms, Can Primary Care Once Again Show Gains?
    March 15, 2012
    Latest News
    Let Your Lawyer Handle the Work Before You Pay Medical Costs
    July 6, 2025
    Top HIPAA-Compliant Messaging Apps for Healthcare Teams
    June 25, 2025
    When Healthcare Ends, the Legal Process Begins: What Families Should Know About Probate and Medical Estates
    June 20, 2025
    Preventing Contamination In Healthcare Facilities Starts With Hygiene
    June 15, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Rubigo Therapeutics Develops Early Assessment and Treatment for Skin Cancer
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Diagnostics > Rubigo Therapeutics Develops Early Assessment and Treatment for Skin Cancer
Diagnostics

Rubigo Therapeutics Develops Early Assessment and Treatment for Skin Cancer

HerinaAyot
HerinaAyot
Share
5 Min Read
SHARE

There are multiple types of skin disorders that could cause anyone concerned about cancer to wonder about a spot on their skin or on a loved one’s skin.  This fear of having cancer is not unfounded as the incidence of skin cancer is increasing at an alarming rate due in large part by ultraviol

There are multiple types of skin disorders that could cause anyone concerned about cancer to wonder about a spot on their skin or on a loved one’s skin.  This fear of having cancer is not unfounded as the incidence of skin cancer is increasing at an alarming rate due in large part by ultraviolet (UV) exposure either over time or to excessive sun burn.  Rubigo Therapeutics is a development stage biotech company focused on developing a technology using an active polymeric material that offers a topically controlled release of small molecules targeted at tissue lesions suspected of being cancerous and longer term, a therapeutic delivery platform.

Although melanoma is the fifth leading cause of death associated with cancer in men and seventh for women, ahead of ovarian, identifying these types of lesions are not always as easy as everyone would like.  Additionally, even squamous-cell carcinoma, which is typically perceived as benign, can become lethal if not addressed early enough.  Early confirmatory feedback that an odd looking mole or lesion is cancerous can be of tremendous value to patients, physicians and healthcare payers to either objectively dismiss a concern or plan an appropriate, timely course of action.

The list of possible market opportunities and possible drug candidates that could be combined with Rubigo Therapeutics’ unique technology is substantial; however, the company has elected to focus its development efforts in skin cancer involving Imiquimod, an immune response modifier, due to a number of competitive factors.

More Read

Mammography Scheduling Portal Helps Improve Screening Attendance in Denmark
Telemedicine Image Collaboration Enhances Patient Safety
More “Conversations” – Not More Health IT – Are What’s Needed To Increase Patient Engagement And Improve Patient Satisfaction
FDA Approves Roche (Genentech) Skin Cancer Drug–Zelboraf
10 Essential Things Every Bio Lab Needs To Have

Imiquimod, which was developed and patented by 3M in the early 90’s and FDA approved in 2006 for genital warts, and subsequently for actinic keratosis and basal cell cancer, has shown clinical effectiveness to the FDA, prescribing physicians and healthcare payers.  This has occurred over the past five years despite a broad array of topical delivery issues, questions involving dosing and adverse effects in patients.  Due to Rubigo Therapeutics’ unique polymer construction, Imiquimod can be easily and consistently loaded and more importantly, delivered in a consistent and reliable fashion transdermally into the patient’s skin where needed.  Early in vitro data suggests this can be done with lower concentrations of the active drug, providing additional control and means to control dosing of the therapeutic molecule than is currently offered by creams.  The company believes that its substantially improved means of delivering a highly effective, market recognized therapeutic molecule for the treatment of skin cancer, both for early assessment and treatment which is protected by fresh intellectual property, makes Rubigo Therapeutics a novel technology entrant in a large, growing worldwide market.

In terms of treatment, all forms of skin cancer can be successfully treated surgically.  From the perspective of healthcare payers such as the Center for Medicaid and Medicare Services (“CMS”) or Private Payer, management of skin cancers are costly and will continue to be costly unless earlier diagnosis and treatment can occur.  Today, non-melanoma and melanoma disorders are estimated to cost as much as $1B and $1.9B per year respectively in the U.S.  Consequently, the need to accelerate earlier assessment of potentially deadly and yet, treatable skin lesions is a very compelling need.  This need is further enhanced when one can improve the information being discussed and utilized between patient and physician to achieve the best clinical outcomes and minimizing surprises and patient dissatisfaction regarding the loss of tissue or worse yet, becoming disfigured.  Rubigo Therapeutics will be a presenting company at OneMedForum NY 2011 June 22-24.

 

TAGGED:diagnosticsRubigo Therapeuticsskin cancer
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

car accident lawsuit
Let Your Lawyer Handle the Work Before You Pay Medical Costs
Policy & Law
July 6, 2025
women dental care
What Is a Smile Makeover and How Much Does It Cost?
Dental health
June 30, 2025
HIPAA-Compliant Messaging Apps
Top HIPAA-Compliant Messaging Apps for Healthcare Teams
Global Healthcare Policy & Law Technology
June 25, 2025
recovering from injury
Rebuilding After Injury: Path to Physical and Emotional Recovery
News
June 22, 2025

You Might also Like

Alzheimer’s Often Misdiagnosed

April 13, 2011
hand touching medical interface
DiagnosticsHealth ReformTechnology

Why do we need a new operating system for effective shared care plans?

March 1, 2016
biopharma beat
BusinessDiagnosticsMedical EducationMedical EthicsMedical InnovationsPolicy & LawPublic Health

BioPharma Beat: Is Commercial Support of CME A Bad Idea?

November 24, 2014

Dermatology Smartphone Apps No Substitute for Doctor’s Visit

October 1, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?